Evidence map›Paper›PMID 36379754›Full record

ArticleVaccine2022

Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons.

Michael L Jackson, C Hallie Phillips, Stacie Wellwood, Erika Kiniry, Lisa A Jackson, Emily T Martin, Arnold S Monto, Huong Q McLean, Edward A Belongia, Manjusha Gaglani and 5 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Michael L JacksonKaiser Permanente Washington Health Research Institute, Seattle WA, United States.
C Hallie PhillipsKaiser Permanente Washington Health Research Institute, Seattle WA, United States.
Stacie WellwoodKaiser Permanente Washington Health Research Institute, Seattle WA, United States.
Erika KiniryKaiser Permanente Washington Health Research Institute, Seattle WA, United States.
Lisa A JacksonKaiser Permanente Washington Health Research Institute, Seattle WA, United States.
Emily T MartinUniversity of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, MI, United States.
Arnold S MontoUniversity of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, MI, United States.
Huong Q McLeanMarshfield Clinic Research Institute, Marshfield, WI, United States.
Edward A BelongiaMarshfield Clinic Research Institute, Marshfield, WI, United States.
Manjusha GaglaniBaylor Scott and White Health, Temple, TX, United States; Texas A&M University College of Medicine, Temple, TX, United States.
Kayan DunniganBaylor Scott and White Health, Temple, TX, United States.
Chandni RaiyaniBaylor Scott and White Health, Temple, TX, United States.
Kempapura MurthyBaylor Scott and White Health, Temple, TX, United States.
Brendan FlanneryU.S. Centers for Disease Control and Prevention. Influenza Division, Atlanta GA, United States.
Jessie R ChungU.S. Centers for Disease Control and Prevention. Influenza Division, Atlanta GA, United States. Electronic address: jchung@cdc.gov.
Kaiser Permanente Washington Health Research Institute · USBaylor Scott & White Health · USCenters for Disease Control and Prevention · USMarshfield Clinic · USUniversity of Michigan · USTemple College · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
US Influenza Vaccine Effectiveness NetworkU01IP001034 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2016 to 2020
$10.0M
Annual Estimates of Influenza Vaccine Effectiveness and Evaluation of Immune Response in a Wisconsin PopulationU01IP001038 · IP · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI BELONGIA, EDWARD · 2016 to 2020
$8.0M
Prospective annual estimates of influenza vaccine effectiveness and burden of diseaseU01IP001037 · IP · KAISER FOUNDATION RESEARCH INSTITUTE · PI JACKSON, MICHAEL L · 2016 to 2020
$7.8M
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse networkU01IP001035 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2016 to 2020
$7.8M
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.U01IP001039 · IP · SCOTT AND WHITE MEMORIAL HOSPITAL · PI GAGLANI, MANJUSHA · 2016 to 2020
$6.5M
ACL HHS U01IP001034ACL HHS U01IP001037ACL HHS U01IP001038ACL HHS U01IP001039Intramural CDC HHS CC999999NCATS NIH HHS UL1 TR001857NCIRD CDC HHS U01 IP001034NCIRD CDC HHS U01 IP001035NCIRD CDC HHS U01 IP001037NCIRD CDC HHS U01 IP001038NCIRD CDC HHS U01 IP001039
6 · The paper itself

Abstract

backgroundEpidemics of seasonal influenza vary in intensity annually, and influenza vaccine effectiveness (VE) fluctuates based in part on antigenic match to circulating viruses. We estimated the incidence of influenza and influenza cases averted by vaccination in four ambulatory care sites in the United States, during seasons when overall influenza VE ranged from 29% to 40%.

methodsWe conducted active surveillance for influenza at ambulatory care settings at four sites within the United States Influenza Vaccine Effectiveness Network. We extrapolated the total number of influenza cases in the source populations served by these organizations based on incidence of medically attended acute respiratory illness in the source population and influenza test results in those actively tested for influenza. We estimated the number of medically attended influenza cases averted based on incidence, vaccine coverage, and VE.

resultsFrom 2016/17 through 2018/19, incidence of ambulatory visits for laboratory-confirmed influenza ranged from 31 to 51 per 1,000 population. Incidence was highest in children aged 9-17 years (range, 56 to 81 per 1,000) and lowest in adults aged 18-49 years (range, 23-32 per 1,000). Medically attended cases averted by vaccination ranged from a high of 46.6 (95 % CI, 12.1- 91.9) per 1,000 vaccinees in children aged 6 months to 8 years, to a low of 6.9 (95 % CI, -5.1- 27.3) per 1,000 vaccinees in adults aged ≥ 65 years. DISCUSSION: Even in seasons with low vaccine effectiveness for a particular virus subtype, influenza vaccines can still lead to clinically meaningful reductions in ambulatory care visits for influenza.

Indexed as

Influenza, HumanInfluenza VaccinesAdultChildHumansInfantPopulation SurveillanceSeasonsUnited StatesVaccinationInfluenza Vaccines

Identifiers

PMID36379754
PMCPMC9732931
OpenAlexW4308841835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.